Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt

NAFLD: early-phase trial registry

9 of 27 indexed NAFLD trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #598 of 28,707 conditions by registered trial count.

27 US clinical trials · 9 currently recruiting · #598 of 28,707 conditions by registered trial count

NAFLD: 27 US clinical trials tracked, 9 recruiting.

NAFLD is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Yale University, running 3 of these trials.

Enrollment posture brief

Registry condition nafld

OPEN 9 | RECR 33% | LATE 1 | EARLY 9 | RANK #598 | SPON 3

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Alopecia Areata55.6%Acute Ischemic Stroke44.4%NAFLD (this)33%Adenocarcinoma25.9%Acne22.2%
Open-enrollment share among volume-matched conditions near NAFLD

NAFLD lists 9 open slots (33% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for NAFLD on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. NAFLD is recruiting below its size-band peers.

    9 of 27 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of NAFLD trials is spread across many organizations.

    Yale University accounts for 3 of 27 trials (11.1%). 21 distinct sponsors appear on at least one study for this condition label.

  3. Typical NAFLD enrolment sits around 72 participants.

    Median target enrolment is 72 among the 27 trials that report a genuine target (sentinel values excluded). 16 of those (59.3%) plan for fewer than 100 participants.

  4. NAFLD splits between interventional and observational designs.

    18 interventional and 9 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 26Phase 31

Open and recent trials

27 total, page 1 of 1

RECRUITING 260 participants

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

Yale University

NCT04634643

RECRUITING NA 250 participants

Reversal of Lipid-Induced Insulin Resistance

Yale University

NCT02193295

RECRUITING 150 participants

Androgens and NAFLD Longitudinal Cohort Study

University of California, San Francisco

NCT06124261

RECRUITING Phase 2 144 participants

Digoxin In NASH (CODIN)

Yale University

NCT06588699

RECRUITING Phase 3 55 participants

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

University of Colorado, Denver

NCT05935826

RECRUITING Phase 2 50 participants

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Virginia Commonwealth University

NCT05424003

RECRUITING Phase 1 50 participants

Bicalutamide Therapy in Young Women With NAFLD and PCOS

University of California, San Francisco

NCT05979389

RECRUITING NA 45 participants

NASH AMPK Exercise Dosing (AMPED) Trial

Milton S. Hershey Medical Center

NCT04987879

RECRUITING NA 32 participants

NAFLD Clinical Care Pathway

VA Office of Research and Development

NCT06671886

ACTIVE NOT RECRUITING 1,250 participants

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

University of California, San Francisco

NCT04795219

ACTIVE NOT RECRUITING 450 participants

LITMUS Imaging Study

University of Oxford

NCT05479721

ACTIVE NOT RECRUITING 400 participants

Nonalcoholic Fatty Liver Disease in HIV Database

Johns Hopkins University

NCT05023044

ACTIVE NOT RECRUITING Phase 2 120 participants

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Hepion Pharmaceuticals

NCT05402371

ACTIVE NOT RECRUITING Phase 2 80 participants

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Merck Sharp & Dohme

NCT06465186

ACTIVE NOT RECRUITING Phase 2 67 participants

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

Neuraly

NCT06410924

ACTIVE NOT RECRUITING 50 participants

Accurate Point of Care Liver Disease Diagnostics

University of California, San Diego

NCT05986916

ACTIVE NOT RECRUITING NA 24 participants

An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

University of Wisconsin, Madison

NCT06354491

ACTIVE NOT RECRUITING Phase 1 21 participants

The Effects of Glucagon on Hepatic Metabolism

Adrian Vella

NCT05500586

ACTIVE NOT RECRUITING NA 20 participants

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

University of Iowa

NCT04861571

COMPLETED 233 participants

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT05669677

COMPLETED 135 participants

Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE

University of California, Los Angeles

NCT04591106

COMPLETED NA 113 participants

Healthy Eating Through Reduction Of Excess Sugar

University of Southern California

NCT02948647

COMPLETED Phase 1 84 participants

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Bird Rock Bio

NCT03261739

COMPLETED NA 72 participants

The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)

Fred Hutchinson Cancer Center

NCT02663544

COMPLETED Phase 2 60 participants

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

University of Colorado, Denver

NCT03919929

COMPLETED NA 55 participants

Healthy Liver - Healthy Brain

University of Texas at Austin

NCT05216796

COMPLETED 25 participants

Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease

Virginia Commonwealth University

NCT02132780

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6
Phase 3 1

Named interventions

Most-linked intervention names on NAFLD records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Standard of care plus sugar-reduction education Other
1 trials
Diet Intervention Behavioral
1 trials
Weight loss diet Other
1 trials
Semaglutide 3mg and 7mg [Rybelsus] Drug
1 trials
Prototype MRE soft flexible passive transducer paddle Device
1 trials
Magnetic resonance elastography (MRE) Diagnostic test
1 trials
RYI-018 Biological
1 trials

US sites by state

Facility locations filed on NAFLD trials. A trial with sites in several states counts in each.

California 10 trials
Texas 7 trials
Virginia 4 trials
Maryland 4 trials
Florida 4 trials
North Carolina 3 trials
Connecticut 3 trials
Colorado 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this NAFLD page

27 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NAFLD condition card totals 27 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.